

Pharma Cold Chain Developments, Outlook & Opportunities

Morgane Hanssens, Business Development Manager Life Science & Healthcare, Port of Antwerp



Pharma Cold Chain Outlook

Morgane Hanssens

Business Development Manager Life Science & Healthcare

15/03/2018



The Antwerp Port Authority: Role









NAUTICAL

Vessel traffic Management

OPERATIONAL

Tug
Dredging
Cranes

INFRASTUCTURE

Dock – Locks Quays – Bridges

Planning
Building
Maintenance
Financing


COMMERCIAL

Harbor dues & Concessions

Customer Relations

Customer Relations






Themes




- 1. Global Flows
- 2. Demanding Industry Needs
- 3. Port Authority Initiatives




Commodities & Shipping Modes





Global pharmaceutical market





Belgium: hot spot for pharmaceuticals





EUR 41 billion export value in 2016

Antwerp at the Heart of the Industry





- □ Deep INLAND location
- □ DeepSEA access





Industry Needs

Quality is Key



INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

EUROPEAN COMMISSION

Guidelines

of 5 November 2013

on Good Distribution Practice of medicinal products for human use

(Text with EEA relevance)

(2013/C 343/01)












M&A enhances need for centralisation





Pharmaceutical Supply Chain








3

Port Authority Initiatives

LSP Pharma landscape





Conclusion

Morgane Hanssens

Business Development Manager Life Science & Healthcare morgane.hanssens@portofantwerp.com +32 3 229 71 08

15/03/2018

